The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans

Inclusion Criteria: 1. Signed and dated informed consent 2. Married female, 18-38 years old 3. Diagnosis of premature ovarian insufficiency: At least two menopausal FSH levels (≥ 20 IU/L) and/or Primary or secondary amenorrhea at least for 6 months 4. Evidence of low ovarian reserve defined as: AMH \< \_0.3 ng/ML \& FSH \>20 IU/L, AFC \< 4, and/or failure of prior attempts of assisted reproductive techniques due to limited ovarian response (poor responder). 5. Normal karyotype 46, XX. 6. Presence of at least one ovary 7. Normal thyroid function as evidence by normal serum Thyroid Stimulating Hormone (TSH) levels. 8. Agree to report any pregnancy to the research staff immediately. 9. Cooperative patient 10. Negative for infectious panel (HIV, HBV, HCV, and VDRL) Exclusion Criteria: 1. Currently breast-feeding 2. Has a history of, or evidence of current malignancy 3. Major mental health disorder that precludes participation in the study 4. Current or recent (within the past 2 weeks) use of the following medications: Oral or systemic corticosteroids, Hormones (estrogen, progestins, oral contraceptives), Danazol, anticoagulants, herbal or botanical supplements with possible hormonal effects. Washout will be allowed. 5. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications 6. Significant anemia (Hemoglobin \<8 g/dL). 7. Untreated deep venous thrombosis, and/or pulmonary embolus 8. Known heart disease (New York Heart Association Class II or higher). 9. Known Liver disease (defined as Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT)\>2 times normal, or total bilirubin \>2.5 mg/dL). 10. Known Renal disease (defined as Blood urea nitrogen (BUN)\>30 mg/dL or serum creatinine \> 1.6 mg/dL). 11. Clinically active autoimmune condition